TWA
SNDX icon

TCI Wealth Advisors’s Syndax Pharmaceuticals SNDX Stock Holding History

TCI Wealth Advisors’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-281
Closed -$5.93K – 1939
2023
Q1 		$5.93K Buy
+281
New +$6.99K ﹤0.01% 1412
2022
Q2 		– Sell
-246
Closed -$4K – 2495
2022
Q1 		$4K Hold
246
– – ﹤0.01% 1784
2021
Q4 		$5K Buy
+246
New +$4.54K ﹤0.01% 1718

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

TCI Wealth Advisors's SNDX Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Syndax Pharmaceuticals (SNDX) in Q2 2023, closing a stake of 281 shares — an estimated $5.93K sold.

TCI Wealth Advisors first reported a position in SNDX in Q4 2021 and held it in 3 quarters. The position peaked at $5.93K in Q1 2023. 166 funds tracked by Wall St. Rank hold SNDX as of Q2 2023.

  • TCI Wealth Advisors reported no remaining Syndax Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • TCI Wealth Advisors sold 281 Syndax Pharmaceuticals shares in Q2 2023, an estimated $5.93K.
  • TCI Wealth Advisors first reported a position in Syndax Pharmaceuticals in Q4 2021 and held it in 3 quarters.
  • TCI Wealth Advisors's Syndax Pharmaceuticals position peaked at $5.93K in Q1 2023.
  • 166 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.